ProPhase Labs
PRPH
PRPH was delisted on the 2nd of January, 2026.
2 hedge funds and large institutions have $2 invested in ProPhase Labs in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 14 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.45% less ownership
Funds ownership: 0.45% → 0% (-0.45%)
88% less funds holding
Funds holding: 17 → 2 (-15)
100% less capital invested
Capital invested by funds: $92.9K → $2 (-$92.9K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 14
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sykon Capital
Harrison,
New York
|
-$28.9K |
| 2 |
Jane Street
New York
|
-$9.82K |
| 3 |
SG
StoneX Group
New York
|
-$8.95K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$8.43K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$7.28K |
PRPH Hedge Fund Activity: Q1 2026 in Review
2 of the 8,184 institutional investors tracked by Wall St. Rank reported a position in ProPhase Labs (PRPH) for Q1 2026, worth a combined $2 — down 100% from $92.9K a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PRPH and 0 opened new positions — a net loss of 14 holders — while 1 trimmed existing stakes and 1 added.
The largest seller was Sykon Capital, exiting entirely with an estimated $28.9K sold.
- 2 institutional investors held ProPhase Labs (PRPH) as of Q1 2026, down from 17 in Q4 2025.
- Funds reported $2 of ProPhase Labs stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new ProPhase Labs positions in Q1 2026 and 14 closed out, a net change of -14 holders.
- The largest ProPhase Labs seller in Q1 2026 was Sykon Capital, an estimated $28.9K sold.
Based on aggregated 13F filings for Q1 2026.